Page 1880 - Hematology_ Basic Principles and Practice ( PDFDrive )

1668.e4 Part X Transplantation

141. Blazar BR, Sharpe AH, Chen AI, et al: Ligation of OX40 (CD134) 165. Lowsky R, Takahashi T, Liu YP, et al: Protective conditioning for acute
regulates graft-versus-host disease (GVHD) and graft rejection in graft-versus-host disease. N Engl J Med 353:1321, 2005.
allogeneic bone marrow transplant recipients. Blood 101:3741, 2003. 166. Edinger M, Hoffmann P, Contag CH, et al: Evaluation of effector cell
142. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al: Blockade of fate and function by in vivo bioluminescence imaging. Methods 31:172,
programmed death-1 engagement accelerates graft-versus-host disease 2003.
lethality by an IFN-gamma-dependent mechanism. J Immunol 167. Nguyen VH, Zeiser R, Dasilva DL, et al: In vivo dynamics of regulatory
171:1272, 2003. T-cell trafficking and survival predict effective strategies to control
143. Nabekura T, Shibuya K, Takenaka E, et al: Critical role of DNAX acces- graft-versus-host disease following allogeneic transplantation. Blood
sory molecule-1 (DNAM-1) in the development of acute graft-versus- 109:2649, 2007.
host disease in mice. Proc Natl Acad Sci USA 107(43):18593–18598, 168. Zhang P, Tey S-K, Koyama M, et al: Induced Regulatory T Cells
2010. Promote Tolerance When Stabilized by Rapamycin and IL-2 In Vivo.
144. Koyama M, Kuns RD, Olver SD, et al: Promoting regulation via the J Immunol 191(10):5291, 2013.
+
inhibition of DNAM-1 after transplantation. Blood 121(17):3511, 169. Ma H, Lu C, Ziegler J, et al: Absence of Stat1 in donor CD4 T cells
2013. promotes the expansion of Tregs and reduces graft-versus-host disease
+
+
145. Csencsits KL, Bishop DK: Contrasting alloreactive CD4 and CD8 T in mice. J Clin Invest 121:2554, 2011.
cells: there’s more to it than MHC restriction. Am J Transplant 3:107, 170. Tawara I, Shlomchik WD, Jones A, et al: A crucial role for host APCs
+
+
2003. in the induction of donor CD4 CD25 regulatory T cell-mediated sup-
146. Korngold R, Sprent J: Features of T cells causing H-2 restricted lethal pression of experimental graft-versus-host disease. J Immunol 185:3866,
graft-vs-host disease across minor histocompatibility barriers. J Exp Med 2010.
155:872, 1982. 171. Matsuoka K, Koreth J, Kim HT, et al: Low-dose interleukin-2 therapy
147. Korngold R, Sprent J: Surface markers of T cells causing lethal graft-vs- restores regulatory T cell homeostasis in patients with chronic graft-
host disease to class I vs class II H-2 differences. J Immunol 135:3004, versus-host disease. Sci Transl Med 5:179ra43, 2013.
1985. 172. Choi SW, Braun T, Chang L, et al: Vorinostat plus tacrolimus and
148. Korngold R, Sprent J: T cell subsets and graft-versus-host disease. mycophenolate to prevent graft-versus-host disease after related-donor
Transplantation 44:335, 1987. reduced-intensity conditioning allogeneic haemopoietic stem-cell
149. Wu CJ, Ritz J: Induction of tumor immunity following allogeneic stem transplantation: a phase 1/2 trial. Lancet Oncol 15(1):87, 2014.
cell transplantation. Adv Immunol 90:133, 2006. 173. Choi SW, Gatza E, Hou G, et al: Histone deacetylase inhibition regu-
+
150. Anderson BE, McNiff J, Yan J, et al: Memory CD4 T cells do not lates inflammation and enhances Tregs after allogeneic hematopoietic
induce graft-versus-host disease. J Clin Invest 112:101, 2003. cell transplantation in humans. Blood 125(5):815, 2015.
151. Chen BJ, Cui X, Sempowski GD, et al: Transfer of allogeneic CD62L- 174. Kanakry CG, Ganguly S, Zahurak M, et al: Aldehyde dehydrogenase
memory T cells without graft-versus-host disease. Blood 103:1534, expression drives human regulatory T cell resistance to posttransplanta-
2004. tion cyclophosphamide. Sci Transl Med 5:211ra157, 2013.
+
152. Zhang Y, Joe G, Zhu J, et al: Dendritic cell-activated CD44hiCD8 T 175. Martelli MF, Di Ianni M, Ruggeri L, et al: HLA-haploidentical
cells are defective in mediating acute graft-versus-host disease but retain transplantation with regulatory and conventional T-cell adoptive
graft-versus-leukemia activity. Blood 103:3970, 2004. immunotherapy prevents acute leukemia relapse. Blood 124(4):638,
153. Maeda Y, Tawara I, Teshima T, et al: Lymphopenia-induced pro- 2014.
liferation of donor T cells reduces their capacity for causing acute 176. Riley JL, June CH, Blazar BR: Human T regulatory cell therapy: take
graft-versus-host disease. Exp Hematol 35:274, 2007. a billion or so and call me in the morning. Immunity 30:656, 2009.
154. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al: L-Selectin(hi) but 177. Hashimoto D, Asakura S, Miyake S, et al: Host NKT cells promote
+
+
not the L-selectin(lo) CD4 25 T-regulatory cells are potent inhibitors Th2 polarization of donor T cells and regulate acute GVHD after
of GVHD and BM graft rejection. Blood 104:3804, 2004. experimental BMT via a STAT6-dependent mechanism. Blood
155. Zhang Y, Joe G, Hexner E, et al: Alloreactive memory T cells are 102:191a, 2003.
responsible for the persistence of graft-versus-host disease. J Immunol 178. Morris ES, MacDonald KP, Rowe V, et al: NKT cell-dependent leuke-
174:3051, 2005. mia eradication following stem cell mobilization with potent G-CSF
+
156. Zhang Y, Joe G, Hexner E, et al: Host-reactive CD8 memory stem analogs. J Clin Invest 115:3093, 2005.
cells in graft-versus-host disease. Nat Med 11:1299, 2005. 179. Morris ES, MacDonald KP, Hill GR: Stem cell mobilization with
157. Blazar BR, Taylor PA: Regulatory T cells. Biol Blood Marrow Transplant G-CSF analogs: a rational approach to separate GVHD and GVL?
11:46, 2005. Blood 107:3430, 2006.
+
158. Cohen JL, Boyer O: The role of CD4 CD25hi regulatory T cells in 180. Banovic T, MacDonald KP, Morris ES, et al: TGF-beta in allogeneic
the physiopathogeny of graft-versus-host disease. Curr Opin Immunol stem cell transplantation: friend or foe? Blood 106:2206, 2005.
18:580, 2006. 181. Wang JW, Howson JM, Ghansah T, et al: Influence of SHIP on the
+
159. Johnson BD, Konkol MC, Truitt RL: CD25 immunoregulatory T-cells NK repertoire and allogeneic bone marrow transplantation. Science
of donor origin suppress alloreactivity after BMT. Biol Blood Marrow 295:2094, 2002.
Transplant 8:525, 2002. 182. Kamradt T, Mitchison NA: Tolerance and autoimmunity. N Engl J Med
160. Hoffmann C, Chow KU, Wolf E, et al: Strong impact of highly active 344:655, 2001.
antiretroviral therapy on survival in patients with human immunode- 183. Wekerle T, Kurtz J, Ito H, et al: Allogeneic bone marrow transplantation
ficiency virus-associated Hodgkin’s disease. Br J Haematol 125:455, with co-stimulatory blockade induces macrochimerism and tolerance
2004. without cytoreductive host treatment. Nat Med 6:464, 2000.
+
+
161. Cohen JL, Trenado A, Vasey D, et al: CD4( )CD25( ) immunoregula- 184. Wekerle T: Transplantation tolerance induced by mixed chimerism. J
tory T cells: new therapeutics for graft-versus-host disease. J Exp Med Heart Lung Transplant 20:816, 2001.
196:401, 2002. 185. Sykes M, Sachs DH: Mixed chimerism. Philos Trans R Soc Lond B Biol
162. Roncarolo MG: The role of interleukin-10 in transplantation and Sci 356:707, 2001.
GVHD. In Ferrara JLM, Deeg HJ, Burakoff SJ, editors: Graft-vs.-host 186. Centers for Disease Control and Prevention, Infectious Diseases Society
disease, ed 2, New York, 1997, Marcel Dekker, Inc., p 693. of America, American Society of Blood and Marrow Transplantation:
163. Young KJ, DuTemple B, Phillips MJ, et al: Inhibition of graft-versus- Guidelines for preventing opportunistic infections among hematopoi-
host disease by double-negative regulatory T cells. J Immunol 171:134, etic stem cell transplant recipients. Biol Blood Marrow Transplant 6:7,
2003. 2000.
−
164. Zeng D, Lewis D, Dejbakhsh-Jones S, et al: Bone marrow NK1.1( ) 187. Van Parijs L, Ibraghimov A, Abbas AK: The roles of costimulation
+
and NK1.1( ) T cells reciprocally regulate acute graft versus host and Fas in T-cell apoptosis and peripheral tolerance. Immunity 4:321,
disease. J Exp Med 189:1073, 1999. 1996.